William G Kaelin

List of PR Articles by Year in descending order

79 PR articles	15,929 PR citations	25011 50 PR h-index	51699 77 g-index
100 documents	25500 doc citations	15030 62 h-index	34566 citing authors

#	Article	IF	PR Citations
1	Induction of DEPP1 by HIF Mediates Multiple Hallmarks of Ischemic Cardiomyopathy. Circulation, 2024, 150, 770-786.	25.2	9
2	Total loss of VHL gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2Î± activity. Proceedings of the National Academy of Sciences of the United States of America, 2024, 121, .	7.6	8
3	Toward a CRISPR-based mouse model of Vhl -deficient clear cell kidney cancer: Initial experience and lessons learned. Proceedings of the National Academy of Sciences of the United States of America, 2024, 121, .	7.6	10
4	Prolonged hypoxia alleviates prolyl hydroxylation-mediated suppression of RIPK1 to promote necroptosis and inflammation. Nature Cell Biology, 2023, 25, 950-962.	16.9	53
5	Sensitivity ofVHLmutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.6	27
6	A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Antiapoptotic Protein in Kidney Cancer. Clinical Cancer Research, 2022, 28, 4689-4701.	6.9	14
7	Mitochondrial remodeling and ischemic protection by G proteinâ€“coupled receptor 35 agonists. Science, 2022, 377, 621-629.	36.4	87
8	Targeting oncoproteins with a positive selection assay for protein degraders. Science Advances, 2021, 7, .	11.0	44
9	DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA. Neuro-Oncology Advances, 2021, 3, i12-i13.	0.9	1
10	Belzutifan, a Potent HIF2Î± Inhibitor, in the Pacakâ€“Zhuang Syndrome. New England Journal of Medicine, 2021, 385, 2059-2065.	43.7	80
11	CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell, 2020, 37, 37-54.e9.	38.5	188
12	2-Oxoglutarate-dependent dioxygenases in cancer. Nature Reviews Cancer, 2020, 20, 710-726.	61.8	193
13	Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. Cell Research, 2020, 31, 80-93.	12.5	86
14	The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes and Development, 2019, 33, 1718-1738.	4.7	103
15	HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species. Science Signaling, 2019, 12, .	5.5	74
16	Peptidic degron for IMiD-induced degradation of heterologous proteins. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2539-2544.	7.6	62
17	Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. Cell Metabolism, 2019, 29, 1166-1181.e6.	26.2	155
18	EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16997-17006.	7.6	15

#	Article	IF	PR Citations
19	Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. Cancer Discovery, 2019, 9, 230-247.	25.6	157
20	Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma. JCI Insight, 2019, 4, .	5.4	29
21	The von Hippelâ€“Lindau Tumor Suppressor Protein. Annual Review of Cancer Biology, 2018, 2, 91-109.	5.4	22
22	Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, .	7.6	13
23	HIF2 Inhibitor Joins the Kidney Cancer Armamentarium. Journal of Clinical Oncology, 2018, 36, 908-910.	21.6	17
24	BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1Î± activation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, .	7.6	25
25	Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell, 2018, 175, 101-116.e25.	34.1	328
26	Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL ^{â^'/â^'} clear cell renal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1027-1032.	7.6	144
27	The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks. Molecular Cell, 2017, 66, 772-779.	13.4	255
28	Common pitfalls in preclinical cancer target validation. Nature Reviews Cancer, 2017, 17, 441-450.	61.8	166
29	HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Science Translational Medicine, 2017, 9, .	12.7	44
30	Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine. Cell, 2016, 166, 126-139.	34.1	225
31	Targeting HIF2 in Clear Cell Renal Cell Carcinoma. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 113-121.	1.6	54
32	PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2. Molecular Cell, 2016, 63, 1006-1020.	13.4	142
33	EGLN1 Inhibition and Rerouting of Î±-Ketoglutarate Suffice for Remote Ischemic Protection. Cell, 2016, 164, 884-895.	34.1	126
34	Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. Journal of Biological Chemistry, 2016, 291, 4256-4265.	2.2	279
35	EglN2 associates with the <scp>NRF</scp>1â€<scp>PGC</scp>1Î± complex and controls mitochondrial function in breastÂcancer. EMBO Journal, 2015, 34, 2953-2970.	7.4	69
36	Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15372-15377.	7.6	28

#	Article	IF	PR Citations
37	Inhibition of the oxygen sensor PHD2 in the liver improves survival in lactic acidosis by activating the Cori cycle. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11642-11647.	7.6	54
38	Genetic Evidence of a Precisely Tuned Dysregulation in the Hypoxia Signaling Pathway during Oncogenesis. Cancer Research, 2014, 74, 6554-6564.	0.6	38
39	Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes and Development, 2014, 28, 1429-1444.	4.7	123
40	Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor. Cancer Cell, 2014, 26, 222-234.	38.5	85
41	A genetic mechanism for Tibetan high-altitude adaptation. Nature Genetics, 2014, 46, 951-956.	26.1	386
42	A Comprehensive Study of the VHL-R200W Chuvash Polycythemia Mutation Reveals a Gradual Dysregulation of the Hypoxia Pathway in Oncogenesis. Blood, 2014, 124, 4020-4020.	4.2	2
43	IDH Mutations, 2-Oxoglutarate-dependent Dioxygenases, and Leukemia. Blood, 2014, 124, SCI-6-SCI-6.	4.2	1
44	Disruption of the Ikaros-Mediated Gene Expression Program in Multiple Myeloma with Immunomodulatory Agents. Blood, 2014, 124, 420-420.	4.2	0
45	SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer. Cancer Cell, 2013, 24, 738-750.	38.5	156
46	Influence of Metabolism on Epigenetics and Disease. Cell, 2013, 153, 56-69.	34.1	817
47	What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes and Development, 2013, 27, 836-852.	4.7	550
48	Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes. Blood, 2012, 120, 3509-3509.	4.2	1
49	Genetic and Functional Studies Implicate HIF1Î± as a 14q Kidney Cancer Suppressor Gene. Cancer Discovery, 2011, 1, 222-235.	25.6	390
50	Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lackingRb1orMen1. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13379-13386.	7.6	149
51	Liver Specific Delivery of siRNA Targeting EGLN Prolyl Hydroxylases Activates Hepatic Erythropoietin Production and Stimulates Erythropoiesis,. Blood, 2011, 118, 3161-3161.	4.2	1
52	New cancer targets emerging from studies of the Von Hippelâ€Lindau tumor suppressor protein. Annals of the New York Academy of Sciences, 2010, 1210, 1-7.	4.1	11
53	Control of Cyclin D1 and Breast Tumorigenesis by the EglN2 Prolyl Hydroxylase. Cancer Cell, 2009, 16, 413-424.	38.5	128
54	Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Medicine, 2009, 1, .	9.7	84

#	Article	IF	PR Citations
55	The von Hippelâ€“Lindau tumour suppressor protein: O2 sensing and cancer. Nature Reviews Cancer, 2008, 8, 865-873.	61.8	665
56	Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway. Molecular Cell, 2008, 30, 393-402.	13.4	3,000
57	Kinase requirements in human cells: III. Altered kinase requirements inVHLâ^'/â^' cancer cells detected in a pilot synthetic lethal screen. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16484-16489.	7.6	140
58	The von Hippelâ€Lindau Tumor Suppressor Protein: An Update. Methods in Enzymology, 2007, , 371-383.	2.1	42
59	Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations. Molecular and Cellular Biology, 2007, 27, 5381-5392.	2.5	107
60	The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase. Cell, 2007, 128, 889-900.	34.1	418
61	pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-ÎºB Agonist Card9 by CK2. Molecular Cell, 2007, 28, 15-27.	13.4	171
62	von Hippel-Lindau Disease. Annual Review of Pathology: Mechanisms of Disease, 2007, 2, 145-173.	31.4	311
63	Failure to prolyl hydroxylate hypoxia-inducible factor Î± phenocopies VHL inactivation in vivo. EMBO Journal, 2006, 25, 4650-4662.	7.4	229
64	Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 105-110.	7.6	290
65	The Concept of Synthetic Lethality in the Context of Anticancer Therapy. Nature Reviews Cancer, 2005, 5, 689-698.	61.8	1,361
66	Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer. Cancer Cell, 2005, 8, 155-167.	38.5	511
67	Binding of pRB to the PHD Protein RBP2 Promotes Cellular Differentiation. Molecular Cell, 2005, 18, 623-635.	13.4	225
68	The von Hippelâ€“Lindau protein, HIF hydroxylation, and oxygen sensing. Biochemical and Biophysical Research Communications, 2005, 338, 627-638.	2.1	201
69	PROLINE HYDROXYLATION AND GENE EXPRESSION. Annual Review of Biochemistry, 2005, 74, 115-128.	17.7	438
70	Inhibition of HIF2Î± Is Sufficient to Suppress pVHL-Defective Tumor Growth. PLoS Biology, 2003, 1, e83.	5.0	560
71	How oxygen makes its presence felt. Genes and Development, 2002, 16, 1441-1445.	4.7	141
72	Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell, 2002, 1, 237-246.	38.5	730

#	Article	IF	PR Citations
73	Molecular basis of the VHL hereditary cancer syndrome. Nature Reviews Cancer, 2002, 2, 673-682.	61.8	818
74	Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity. Oncogene, 2000, 19, 5703-5711.	6.7	21
75	Ubiquitination of hypoxia-inducible factor requires direct binding to the Î²-domain of the von Hippelâ€“Lindau protein. Nature Cell Biology, 2000, 2, 423-427.	16.9	1,507
76	The p53 gene family. Oncogene, 1999, 18, 7701-7705.	6.7	178
77	Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function. Science, 1999, 284, 455-461.	36.4	833
78	Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nature Medicine, 1997, 3, 1145-1149.	39.5	162
79	Tumour suppression by the human von Hippel-Lindau gene product. Nature Medicine, 1995, 1, 822-826.	39.5	665